Oppenheimer Holdings, Inc. set a $85.00 target price on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in a research note issued to investors on Tuesday morning. The brokerage currently has a buy rating on the stock.
Several other equities research analysts have also recently weighed in on the company. Jefferies Group LLC reissued a buy rating and set a $69.00 price objective (up from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. ValuEngine raised Neurocrine Biosciences from a sell rating to a hold rating in a research note on Friday, September 1st. BMO Capital Markets reissued an outperform rating and set a $84.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, October 5th. Robert W. Baird reissued an outperform rating and set a $66.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, September 21st. Finally, Leerink Swann reissued an outperform rating and set a $72.00 price objective (up from $67.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 10th. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. Neurocrine Biosciences presently has a consensus rating of Buy and a consensus target price of $78.88.
Shares of Neurocrine Biosciences (NASDAQ NBIX) opened at $72.28 on Tuesday. Neurocrine Biosciences has a twelve month low of $37.35 and a twelve month high of $75.98. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same period last year, the firm posted ($0.43) earnings per share. analysts predict that Neurocrine Biosciences will post -1.74 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by BBNS and is the property of of BBNS. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/neurocrine-biosciences-inc-nbix-given-a-85-00-price-target-at-oppenheimer-holdings-inc/1783023.html.
In related news, insider Dimitri E. Grigoriadis sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the sale, the insider now owns 77,691 shares in the company, valued at $5,794,194.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Darin Lippoldt sold 9,900 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $73.05, for a total value of $723,195.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 150,710 shares of company stock worth $9,758,593. Insiders own 4.80% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. California Public Employees Retirement System boosted its holdings in shares of Neurocrine Biosciences by 1.5% in the third quarter. California Public Employees Retirement System now owns 181,900 shares of the company’s stock valued at $11,147,000 after purchasing an additional 2,600 shares during the period. Davidson Kempner Capital Management LP boosted its holdings in shares of Neurocrine Biosciences by 50.8% in the third quarter. Davidson Kempner Capital Management LP now owns 119,300 shares of the company’s stock valued at $7,311,000 after purchasing an additional 40,200 shares during the period. Crestline Management LP boosted its holdings in shares of Neurocrine Biosciences by 41.1% in the third quarter. Crestline Management LP now owns 63,029 shares of the company’s stock valued at $3,862,000 after purchasing an additional 18,371 shares during the period. Perceptive Advisors LLC boosted its holdings in shares of Neurocrine Biosciences by 33.9% in the third quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock valued at $293,629,000 after purchasing an additional 1,214,000 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Neurocrine Biosciences by 2.6% in the third quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock valued at $337,516,000 after purchasing an additional 140,639 shares during the period.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with our FREE daily email newsletter.